Oxygen-sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension

dc.contributor.authorMorales-Cano, Daniel
dc.contributor.authorBarreira, Bianca
dc.contributor.authorOláiz Navarro, Beatriz
dc.contributor.authorCallejo, María
dc.contributor.authorMondejar-Parreño, Gema
dc.contributor.authorEsquivel-Ruiz, Sergio
dc.contributor.authorLorente, José Angel
dc.contributor.authorMoreno, Laura
dc.contributor.authorBarberà i Mir, Joan Albert
dc.contributor.authorCogolludo, Ángel
dc.contributor.authorPerez-Vizcaino, Francisco
dc.date.accessioned2022-03-02T14:02:51Z
dc.date.available2022-03-02T14:02:51Z
dc.date.issued2021-01-21
dc.date.updated2022-03-02T14:02:51Z
dc.description.abstractCurrent approved therapies for pulmonary hypertension (PH) aim to restore the balance between endothelial mediators in the pulmonary circulation. These drugs may exert vasodilator effects on poorly oxygenated vessels. This may lead to the derivation of blood perfusion towards low ventilated alveoli, i.e., producing ventilation-perfusion mismatch, with detrimental effects on gas exchange. The aim of this study is to analyze the oxygen-sensitivity in vitro of 25 drugs currently used or potentially useful for PH. Additionally, the study analyses the effectiveness of these vasodilators in the pulmonary vs. the systemic vessels. Vasodilator responses were recorded in pulmonary arteries (PA) and mesenteric arteries (MA) from rats and in human PA in a wire myograph under different oxygen concentrations. None of the studied drugs showed oxygen selectivity, being equally or more effective as vasodilators under conditions of low oxygen as compared to high oxygen levels. The drugs studied showed low pulmonary selectivity, being equally or more effective as vasodilators in systemic than in PA. A similar behavior was observed for the members within each drug family. In conclusion, none of the drugs showed optimal vasodilator profile, which may limit their therapeutic efficacy in PH.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec719288
dc.identifier.issn2076-3921
dc.identifier.urihttps://hdl.handle.net/2445/183685
dc.language.isoeng
dc.publisherMDPI
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/antiox10020155
dc.relation.ispartofAntioxidants, 2021, vol. 10, num. 2, p. 155
dc.relation.urihttps://doi.org/10.3390/antiox10020155
dc.rightscc-by (c) Morales-Cano, Daniel et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationVasodilatadors
dc.subject.classificationHipertensió pulmonar
dc.subject.otherVasodilators
dc.subject.otherPulmonary hypertension
dc.titleOxygen-sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
719288.pdf
Mida:
1.24 MB
Format:
Adobe Portable Document Format